AI-generated analysis. Always verify with the original filing.
Halozyme Therapeutics reported record full year 2025 revenue of $1.397 billion, a 38% year-over-year increase, and reiterated its 2026 financial guidance. The company completed acquisitions of Elektrofi and Surf Bio, and issued $1.5 billion in convertible notes.
Event Type
Disclosure
Mandatory
Variant
8-K
of this report and shall not be deemed “ filed ” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “ Exchange Act ” ) or other
Financial Statements and Exhibits. Exhibit No. Description 99.1 Press release dated February 17, 2026 104 Cover Page Interactive Data File (formatted as inline
| Metric | Value | Basis |
|---|---|---|
| Total Revenue | $1.4K | |
| Royalty Revenue | $867.80 | |
| Net Income | $316.90 | GAAP |
| Adjusted EBITDA | $657.60 | Non-GAAP |
| Diluted EPS | $2.56 | GAAP |
| Diluted EPS | $4.15 | Non-GAAP |
Acquisition / Disposition
Material Agreement
Debt / Financing